| 영문 | activation | 한글 | 활성, 활성화 |
|---|---|---|---|
| 설명 | 일반적으로, 생체나 생체 물질이 그 기능을 활발하게 나타내게 되는 것, 예를 들면 ① 촉매 등에서, 그 표면 상태의 변화나, 다른 물질의 첨가 등에 의하여, 그 기능이 현저하게 높아지는 것. ② 효소전구체의 활성화로서 효소작용을 가지지 않는 효소 전구체가 활성있는 효소로 변화는 것. 또 황화수소나 시안화수소산 등으로 파파인이 활성화되는 경우도 있다. |
||
| 영문 | gene | 한글 | 유전자 |
|---|---|---|---|
| 설명 | 유전자는 길게 띠를 형성한 DNA분자의 일부분으로 한 가지 물질을 만드는데 필요한 모든 정보를 갖춘 기능적인 단위이다. 예를 들어 인슐린이라는 물질의 유전자라고 하면 사람의 세포내에 있는 긴 DNA 분자 중에서 인슐린이라는 물질을 만드는데 필요한 모든 정보를 가지고 있는 한 부분을 가리키는 말이다. 고전적인 생물학에서는 유전자가 표현형을 결정하거나 지정하는 염색체의 일부분이라고 정의되었지만, 오늘날에는 유전자에 대해서 분자적 정의가 제안되고 있으며 그 정의는 하나의 유전자는 하나의 효소를 결정 또는 암호화하는 유전물질의 일부분이라는 개념으로 이것이 이른바 1개의 유전자 1개 효소가설(one gene-one enzyme hypothesis)이다. 즉 1개의 유전자는 1개의 효소를 제작하는데 필요한 유전정보를 가진다는 것이다. 현재 이 가설이 받아들여지고 있다. |
||
| 영문 | gene therapy | 한글 | 유전자요법 |
|---|---|---|---|
| 설명 | 유전병을 치료할 목적으로, 정상적으로 기능하는 단일유전자 혹은 복수유전자를 어떤 기원에서 얻어내어 생세포에 도입하는 것. 유전물질은 유전자삽입 조작에 의해 수용세포에로 도입된다. 즉, 유전자를 끼워 넣은 새로운 세포를 사용하는 치료로서 1980년 미국의 학자가 지중해빈혈환자에게 강행하여 비판을 받았지만, 미국 국립보건연구소는 1990년 9월 아데노신 데아미나아제(adenosine deaminase, ADA) 결핍증 환자의 림프구에 ADA 유전자를 끼워 넣는 치료를 시작한 이래 현재는 암을 포함한 많은 질병들을 치료하는 목적으로 쓰인다. |
||
| LAG | labiogingival; leukocyte antigen group; linguo-axiogingival; lymphangiogram; lymphocyte activation g... |
|---|---|
| RAS | 1) Reticular Activating(Activation) System 2) Renal Artery Stenosis |
| VAT | 1) Ventricular Activation Time 2) Video-Assisted Thoracoscopy |
| ADR | activation, depression, repetition [in bone remodeling]; adrenodoxin reductase; Adriamycin; adverse ... |
| AE | above-elbow [amputation]; acrodermatitis enteropathica; activation energy; adult erythrocyte; advers... |
| LAG-3 | Lymphocyte activation gene-3 |
|---|---|
| Kact | Activation constants |
| AD | activation domain |
| AF-1 | Activation function 1 |
| AICD | Activation induced cell death |
| gene activation | The process of activation of a gene so that it is expressed at a particular time. This process is crucial in growth and development. (05 Mar 2000) |
|---|
| activation | <radiobiology> Activation occurs when a particle interacts with an atomic nucleus, shifting the nucleus into an unstable state, and causing it to become radioactive. In fusion research, where deuterium-tritium is a common fuel mixture, the neutron released when (D + T) combine to form (4He + n) can activate the reactor structure. In this case the 4He is inert, the neutron sticks to another nucleus, and the neutron + nucleus reaction creates an actvation product. Sometimes called radioactivation. See: activation product, activation analysis. (09 Oct 1997) |
|---|---|
| activation analysis | <radiobiology> Method for identifying and measuring chemical elements in a sample of material. Sample is first made radioactive by bombardment with neutrons, charged particles, or gamma rays. Newly formed radioactive atoms in the sample then give off characteristic radiations (such as gamma rays) that tell what kinds of atoms are present, and how many. (09 Oct 1997) |
| activation energy | <chemistry> The amount of energy (expressed in joules) that is needed to convert all the molecules in one mole of a reacting substance from a ground state to the transition state. (06 May 1997) |
| activation product | <radiobiology> The unstable nucleus formed when activation occurs. (See activation above.) (09 Oct 1997) |
| amino acid activation | The first step of protein synthesis, whereby an amino acid reacts with adenosine triphosphate in the presence of aminoacyl RNA synthetase to produce an amino acid adenylate, which provides the energy necessary for the attachment of the amino acid to a specific transfer RNA molecule. (12 Dec 1998) |
| macrophage activation | The process of altering the morphology and functional activity of macrophages so that they become avidly phagocytic. It is initiated by lymphokines, such as the macrophage activation factor (maf) and the macrophage migration-inhibitory factor (mmif), immune complexes, c3b, and various peptides, polysaccharides, and immunologic adjuvants. (12 Dec 1998) |
| Gibbs energy of activation | The Gibbs energy that must be added to that already possessed by a molecule or molecules in order to initiate a reaction. (05 Mar 2000) |
| virus activation | The mechanism by which latent viruses, such as genetically transmitted tumour viruses or prophages of lysogenic bacteria, are induced to replicate and are released as infectious viruses. It may be effected by various endogenous and exogenous stimuli, including B-cell lipopolysaccharides, glucocorticoid hormones, halogenated pyrimidines, ionizing radiation, ultraviolet light, and superinfecting viruses. (12 Dec 1998) |
| cis activation | <molecular biology> Activation of a gene by an activator located on the same chromosome i.e. Not by a diffusible product. (18 Nov 1997) |
| complement activation | The sequential activation of serum components c1 through c9, initiated by an erythrocyte-antibody complex or by microbial polysaccharides and properdin, and producing an inflammatory response. (12 Dec 1998) |
| platelet activation | A series of progressive, overlapping events triggered by exposure of the platelets to subendothelial tissue. These events include shape change, adhesiveness, aggregation, and release reactions. When carried through to completion, these events lead to the formation of a stable haemostatic plug. (12 Dec 1998) |
| neutron activation analysis | Activation analysis in which the specimen is bombarded with neutrons. Identification is made by measuring the resulting radioisotopes. (12 Dec 1998) |
| neutrophil activation | The process in which the neutrophil is stimulated by diverse substances, resulting in degranulation and/or generation of reactive oxygen products, and culminating in the destruction of invading pathogens. The stimulatory substances, including opsonised particles, immune complexes, and chemotactic factors, bind to specific cell-surface receptors on the neutrophil. (12 Dec 1998) |
| EEG activation | The low voltage, fast pattern of attentive wakefulness. (05 Mar 2000) |
| trans-activation (genetics) | Increased rate of gene expression directed by either viral or cellular proteins. These regulatory factors (diffusible gene products) act in trans -- that is, act on homologous or heterologous molecules of DNA. (cis-acting factors act only on homologous molecules.) (12 Dec 1998) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|